Grantham, Mayo, Van Otterloo & Co (GMO)
VRTX icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Vertex Pharmaceuticals VRTX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-100,000
Closed -$7.37M – 650
2016
Q4 		$7.37M Hold
100,000
– – 0.04% 217
2016
Q3 		$8.72M Buy
+100,000
New +$9.45M 0.04% 217

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s VRTX Position: Q3 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 58,506 shares — an estimated $20.6M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in VRTX in Q3 2016 and held it in 10 quarters. The position peaked at $33.8M in Q4 2022. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 58,506 Vertex Pharmaceuticals shares in Q3 2023, an estimated $20.6M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Vertex Pharmaceuticals in Q3 2016 and held it in 10 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Vertex Pharmaceuticals position peaked at $33.8M in Q4 2022.
  • 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2023, filed 13 Nov 2023.